Studies had shown that Isorhamnetin could hinder IKK/IKB/NF‐KB/iNOS signaling pathway and reduce interleukin‐1β(IL‐1β), interleukin‐6(IL‐6), and other inflammatory factors to achieve the effect of anti‐DM [47]. Here, IL1B is linked to diabetes mellitus.